R M Pokorny1, L Hunt, S Galandiuk. 1. Department of Surgery, University of Louisville School of Medicine, KY 40292, USA.
Abstract
BACKGROUND/AIMS: Many tumor markers have been utilized in the follow-up care of colorectal cancer patients. No marker, however, has proven reliably accurate in detecting recurrent disease. METHODS: The strengths and weaknesses of currently available tumor markers are reviewed, with attention to related cost and efficacy. RESULTS: Tumor antigens, enzymes, and genetic markers have been used as tumor markers. CEA and CA 19.9 are the most widely utilized; however, genetic markers are the most promising for the future. CONCLUSIONS: Currently available markers have significant limitations. Development of genetic markers may greatly enhance our ability to predict prognosis and the need for adjuvant therapy. Marker-guided therapy may play an increasing role in this disease. Copyright 2000 S. Karger AG, Basel
BACKGROUND/AIMS: Many tumor markers have been utilized in the follow-up care of colorectal cancerpatients. No marker, however, has proven reliably accurate in detecting recurrent disease. METHODS: The strengths and weaknesses of currently available tumor markers are reviewed, with attention to related cost and efficacy. RESULTS:Tumor antigens, enzymes, and genetic markers have been used as tumor markers. CEA and CA 19.9 are the most widely utilized; however, genetic markers are the most promising for the future. CONCLUSIONS: Currently available markers have significant limitations. Development of genetic markers may greatly enhance our ability to predict prognosis and the need for adjuvant therapy. Marker-guided therapy may play an increasing role in this disease. Copyright 2000 S. Karger AG, Basel
Authors: Yee Soo Chae; Jong Gwang Kim; Sang Kyun Sohn; Yoon Young Cho; Byung Min Ahn; Joon Ho Moon; Seoung Woo Jeon; Jae Yong Park; In Taek Lee; Gyu Seog Choi; Soo-Han Jun Journal: J Korean Med Sci Date: 2008-06 Impact factor: 2.153
Authors: Paolo Guazzi; Davide Zocco; Sergejs Isajevs; Natasa Zarovni; Laura Bianciardi; Mart Toots; Armands Sivins; Marcis Leja; Antonio Chiesi; Francesco Lozupone Journal: Transl Cancer Res Date: 2020-11 Impact factor: 1.241